Plasma pTau 217/β-amyloid 1–42 ratio for enhanced accuracy and reduced uncertainty in detecting amyloid pathology
Blood biomarkers have the potential to revolutionize Alzheimer's disease diagnosis, offering advantages over CSF and PET due to their accessibility, scalability and cost-effectiveness. This study evaluated the effectiveness of individual plasma biomarkers, such as phosphorylated Tau (pTau) 217, as well as biomarker combinations, with a focus on the pTau 217/β-Amyloid (Aβ) 1–42 ratio to predict amy
